Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol-Reference-Cited by-同舟云学术

Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol

Published:2023-07 Issue:7 Volume:29 Page:791-806
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Sethi Sanjay¹,Palli Swetha R²,Bengtson Lindsay G S³²,Buysman Erin K³,Clark Brendan²,Sargent Andrew³,Shaikh Asif²,Ferguson Gary T⁴

Affiliation:

1. Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY.

2. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.

3. Optum Life Sciences, Eden Prairie, MN.

4. Department of Medicine, Pulmonary Research Institute of Southeast Michigan, Farmington Hills.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference35 articles.

1. The Economic Burden of COPD

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review

3. A Systematic Literature Review of the Humanistic Burden of COPD

4. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline

5. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisión narrativa de la terapia inhalatoria en la EPOC;Medicina de Familia. SEMERGEN;2024-10

2. Overuse of long-acting β ₂ -agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns;Postgraduate Medicine;2023-11-17